The FDA approved the Oncomine Dx Target Test for identifying HER2-mutant NSCLC patients eligible for Hernexeos, an oral tyrosine kinase inhibitor. Hernexeos offers a new treatment option for ...
(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
(RTTNews) - Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement with British drug major AstraZeneca Plc. (AZN, AZN.L) for the ...
(MENAFN- GlobeNewsWire - Nasdaq) Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In addition to this, strategic pharmaceutical ...
The universe of precision medicine in oncology is large and expanding. With new targeted drugs and companion testing, people with mutation-driven cancers now have care opportunities that have never ...
The U.S. Department of Health and Human Services Office of Inspector General (OIG) once again addressed an industry-sponsored genetic testing program, posting a favorable decision on July 2, 2025 in ...
Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...
The FDA’s approval on Thursday for BioMarin’s Roctavian gene therapy for severe hemophilia A came with a second approval attached: for a companion diagnostic that can identify which patients may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results